Here’s why Oxford Nanopore Technologies stock is up 15% in the FTSE 250

This innovative FTSE 250 stock has had a solid start to the year, rising 15% in just two days. Is it time I considered adding it to my portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Oxford Nanopore Technologies (LSE: ONT) stock was the biggest riser in the FTSE 250 index yesterday (13 January). Shares of the gene-sequencing firm rose 10% then another 5% today to reach 149p.

However, the stock is still down more than 75% since listing in late 2021. Here, I’ll take a look at what has caused the recent jump and assess whether it’s a good fit for my portfolio.

Created with Highcharts 11.4.3Oxford Nanopore Technologies Plc PriceZoom1M3M6MYTD1Y5Y10YALL30 Sep 202114 Jan 2025Zoom ▾Jan '22Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25202220222023202320242024www.fool.co.uk

Encouraging update

For those unfamiliar, Oxford Nanopore makes cutting-edge DNA/RNA sequencing devices that enable real-time analysis of genetic material. They’re used for scientific research across the healthcare and life sciences industries.

Should you invest £1,000 in Oxford Nanopore Technologies Limited right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Oxford Nanopore Technologies Limited made the list?

See the 6 stocks

Yesterday, the firm released a full-year trading update. In this, we learnt that underlying revenue growth in the second half was approximately 34% at constant currency. This was an acceleration over the first half, enabling the company to achieve £183m in revenue, in line with market expectations.

That would represent year-on-year growth of 11% on a constant currency basis. That’s not bad considering the overall life sciences sector faced challenging conditions in 2024.

CEO Gordon Sanghera commented: “Looking beyond 2025, our highly differentiated platform and deep innovation pipeline coupled with strengthened commercial and operational capabilities combined with a strong balance sheet, position us well to deliver long-term, sustainable, above-market growth.”

Encouragingly, the gross margin is set to be slightly above the previously expected 57%. And management anticipates the gross margin reaching 62% by 2027, with revenue growing at a compound annual growth rate of more than 30% between 2024 and that date. It also reaffirmed a target of adjusted EBITDA breakeven in 2027.

No profits yet

Of course, an ambition to reach adjusted EBITDA breakeven in two years indicates that the firm is still deeply unprofitable. Indeed, it doesn’t expect to become cash flow positive until at least 2028.

Clearly, the losses add risk to the investment case. And they almost certainly explain why the share price has struggled since late 2021 when the era of near-0% interest rates came to an end.

We won’t get the full-year earnings until 4 March. Looking at the forecasts though, I’m seeing losses above £100m for both last year and this one.

On the plus side, the firm ended 2024 with £403m in cash, so remains well-capitalised. It should be capable of becoming cash flow positive with the resources at hand. If it can do so, while hitting its revenue growth targets, the share price could end up much higher than today’s 149p.

Should I invest?

Oxford Nanopore’s products are based on innovative technology and it appears to be taking market share during a challenging time. The more devices it sells, the more recurring revenue it gets from consumables and software services.

With a modest market cap of £1.4bn, the firm could become a takeover target. However, it can be dangerous to invest on the basis that a business might be acquired at a higher price.

Recently, I’ve made a hash of picking stocks in the healthcare sector. My holding in Moderna continues to take a battering (down another 16% yesterday), while medical device firm Creo Medical has unperformed too. Even Novo Nordisk is struggling lately.

With Oxford Nanopore stock trading at a premium 7.6 times sales, I’m going to give this one a miss for now.

Should you buy Oxford Nanopore Technologies Limited now?

Don’t make any big decisions yet.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.

And he believes they could bring spectacular returns over the next decade.

Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows...

When such enormous changes hit a big industry, informed investors can potentially get rich.

So, with his new report, Mark’s aiming to put more investors in this enviable position.

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Creo Medical Group Plc, Moderna, and Novo Nordisk. The Motley Fool UK has recommended Moderna and Novo Nordisk. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£20K invested in Tesla stock last April is now worth…

Despite all the bad headlines lately, Tesla stock has put in a storming performance over a 12-month timeframe. Is this…

Read more »

Investing Articles

If a 40 year old invests £600 a month in a SIPP, here’s what they could have by retirement

With no retirement savings at 40, an investor could put £600 a month into a SIPP and grow its value…

Read more »

Stack of British pound coins falling on list of share prices
Investing Articles

Why hasn’t its 9.9% yield boosted the Phoenix share price?

Phoenix Group has a dividend close to double digits, but saw a weak share price performance in recent years. Christopher…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

With average 10% yields, these mid-cap FTSE shares could supercharge a passive income portfolio

Some of the best passive income gems can be found on the UK's smaller indexes like the FTSE 250 and…

Read more »

A coin being dropped into a piggy bank
Investing Articles

As the Barclays share price tanks 19% in 2 days, is this a great buying opportunity?

As a trade war sends the Barclays share price into a tailspin, Andrew Mackie steps back to look at the…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is Fundsmith Equity still a good choice for a Stocks and Shares ISA in 2025?

Many Britons hold the Fundsmith Equity fund in their Stocks and Shares ISAs. Is this still a good move? Edward…

Read more »

Investing Articles

Nvidia stock is down 24% this year. Time to buy the dip?

Christopher Ruane has been eyeing Nvidia stock as a potential addition to his portfolio for a while. Is a recent…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Down 25% since January, this resilient dividend stock’s catching my eye

Maintaining the UK’s rail, water, and energy infrastructure isn’t the most exciting business. But it has made this a solid…

Read more »